Founded in 2018 by renowned geriatrician Dr. Lakshmipathy Ramesh, Geri Care delivers a holistic 360-degree care model tailored for senior citizens. Its offerings include multi-speciality hospitals, assisted living centres, home care services, and exclusive senior citizen clinics. With over 50 years of combined expertise in geriatric care, Geri Care has established itself as a trusted leader in eldercare, serving tens of thousands of seniors across South India, especially in Chennai.

Geri Care plans to use the funds to broaden its services across major cities in southern India, including Bengaluru, Hyderabad, Kochi, and Coimbatore. This quarter, the company aims to open new assisted living facilities in Ulsoor, Bengaluru, and Velachery, Chennai. Additionally, it is developing specialized centres of excellence in geriatric oncology, urology, cardiology, and ortho-geriatrics as part of its network of multi-speciality hospitals dedicated exclusively to elderly care.

Lakshmipathy Ramesh, founder and managing director of Geri Care Health Services, said, “At Geri Care, we strive to make best-in-class geriatric care accessible to our senior community and their families and to enhance the quality of their life, promote independence, well-being, and dignity. We are excited to partner with InvAscent to further our mission of providing holistic and compassionate care to the elderly. The InvAscent team, with their deep understanding of the healthcare space, will be valuable partners in this growth journey. Their investment and partnership will enable us to expand our services and reach more seniors needing specialized healthcare.”

Nithya Govind, managing director of InvAscent, said, “Geri Care is a pioneer in creating an innovative continuum care model, redefining eldercare in India. We are very excited to partner with Dr Ramesh and the team of Geri Care in their growth journey. Our investment aims to support Geri Care’s expansion plans and enhance its capabilities to address the growing needs of the elderly population in India.”

Veda Corporate Advisors acted as the sole financial advisor to Geri Care for this transaction.

The deal expects to close after receiving regulatory approvals and meeting certain conditions outlined in the agreement.

According to PIF, this transaction will bolster the local information and communication technology (ICT) ecosystem, supporting the fund’s strategy in line with Saudi Arabia’s Vision 2030. The acquisition aims to leverage digital transformation to generate high-skill jobs, stimulate economic growth, and strengthen Elm’s leadership in the ICT sector. It will also drive innovation, promote the localization of technology and expertise, and expand Elm’s ability to offer a comprehensive range of ICT products, services, and solutions.

The statement said that the ICT sector is among PIF’s strategic priority investment sectors and is a key enabler of other key industries, including entertainment, financial services, healthcare, transport and logistics, utilities, and renewables.

“PIF is committed to enabling the creation of national champions who contribute to driving the development and growth of the Saudi economy. PIF’s sale of Thiqah to Elm will contribute to enhancing the vital role of the ICT sector and will strengthen efforts to localize technology and drive innovation,” Head of Technology and Media, MENA Investments, at PIF Shahd Attar said.

Elm CEO Mohammad Abdulaziz Alomair said, “This is an important transaction for Elm, as it enhances integration, rationalizes spending, increases profitability, and provides qualitative advantages for both parties and the market.”

“The combined integrated entity will be better able to create advanced national smart services to serve market requirements and clients’ needs. It will also contribute to facilitating innovative operations and capabilities to develop products in the business field with cost advantages while achieving economies of scale,” he added.

The acquisition of Thiqah by Elm marks a significant step in enhancing Saudi Arabia’s digital transformation goals as part of the Vision 2030 initiative. This strategic move will strengthen the local ICT ecosystem, foster innovation, and create high-skill job opportunities while positioning Elm as a key leader in the sector. By expanding its portfolio of smart technology solutions, Elm is well-poised to drive the continued growth of the ICT industry in Saudi Arabia, further contributing to the nation’s economic development and technological advancements.

The funds will scale operations by expanding sales efforts and fast-tracking the Generative AI Feature Suite development for its Health AI Platform.

This platform includes advancements in fraud detection, streamlined claims processing, and personalized clinical care, aiming to drive innovation in healthcare.

The capital will also be used for team expansion, infrastructure enhancements, and R&D initiatives to solidify its position as a leader in health tech solutions.

Established in 2020 by Ashish Chaturvedi, with Swadeep Singh later joining as Co-Founder, Consint.AI is a trailblazer in Generative AI-powered healthcare fraud detection and risk management, committed to revolutionizing healthcare transactions and personalized care.

The company focuses on streamlining healthcare claims processing to make it more affordable and efficient through innovative platforms like Risk.ai, which enhances insurance transaction efficiency and fraud prevention, and CIPHR.ai, designed to improve critical patient management and simplify claims generation.

Leveraging advanced Generative AI technologies, Consint.AI empowers businesses in emerging markets and the U.S. to deliver value-based care, boost operational efficiency, and achieve sustainable growth.

Over the past year, Consint.AI has grown significantly, expanding its presence across India, the Middle East, and Africa. The startup recently introduced CIPHR.ai, an AI-powered platform designed specifically for hospitals, built on proprietary Generative AI models to transform personalized care in critical patient management.

CIPHR.ai delivers intelligence at the point of care and streamlines claims transactions, improving efficiency for healthcare providers. Targeted at emerging health markets and the U.S. Accountable Care Organization (ACO) sector, the platform leverages Generative AI to meet the dynamic demands of modern healthcare systems.

Consint.AI reported Rs 10 crore in signed contracts in the past two quarters, including several multi-year deals with prominent insurance providers and hospital networks. This underscores strong market validation and a growing demand for its innovative solutions, particularly in Generative AI and Document Forensics.

Ashish Chaturvedi, Founder and CEO of Consint, said, “This current market traction and milestones highlight the transformative potential of Generative AI in reshaping healthcare as we know it. At Consint, we are pioneering GenAI-driven platforms like CIPHR.ai and Risk.ai to solve complex challenges in healthcare transactions and personalized care. Our focus remains on advancing our Generative AI capabilities to drive innovation, deliver impactful solutions, and empower businesses globally to achieve seamless operations and value-based care. This funding accelerates our mission to lead the charge in AI-powered healthcare transformation.”

Manoj Agarwal, managing partner at Seafund, said, “Our focus on emerging tech like GenAI, deep tech, IoT, and sustainability has been the guiding force when it comes to backing unique and innovative startups. Consent.AI’s laser-sharp focus on solving the problem of healthcare Insurance claims processing and fraud detection, improving the performance of Insurance and Healthcare institutions is a multi-billion dollar problem to solve, and we believe that we have the necessary expertise and network to help the company grow and reach its ambitions.”

In a regulatory filing, the Sanjeev Bikhchandani-led company announced that Redstart has secured board approval to acquire 385 compulsorily convertible preference shares of Brainsight. Established in 2019 by Laina Emmanuel and Rimjhim Agrawal, Brainsight specializes in AI-driven solutions for functional brain mapping, with its current offerings including two products, Voxelbox and Snowdrop.

Voxelbox provides clinicians with an fMRI processing engine and machine learning models for report generation, while Snowdrop is a patient care application.

According to the filing, Brainsight reported a loss of INR 4.76 Cr during the 2023-24 financial year (FY24), currently valued at INR 3.74 Cr.

Info Edge has been actively investing in recent times. Last month, the internet company announced plans to invest INR 4 Cr in its portfolio company, LegitQuest, through its wholly-owned subsidiary, Startup Investments (Holdings) Ltd. Earlier, in October, the company disclosed that its executive directors’ committee approved an investment of INR 30 Cr in Redstart Labs. Info Edge’s portfolio includes prominent listed companies like foodtech leader Zomato, insurtech firm PB Fintech, and unlisted edtech company Adda247.

In its financial results for Q2 FY25, Info Edge reported a significant 64.6% drop in net profit, which fell to INR 84.73 Cr from INR 239.74 Cr in the same quarter of the previous year. Despite the decline in profit, the company saw a nearly 12% rise in operating revenue, reaching INR 700.82 Cr, compared to INR 625.84 Cr in Q2 FY24.

While Info Edge faces a dip in profitability, it continues to pursue strategic investments, signaling confidence in its long-term growth prospects despite short-term challenges.

The company plans to use the funds to enhance its technology, scale its operations, and drive innovation in diagnostics to meet the growing demand for efficient and accessible healthcare solutions in India.

The company plans to use the funds to expand its products, grow its team, and drive innovation in diagnostics. Known for its at-home sample collection within an hour, extended operating hours, and six-hour report delivery, Orange Health Labs focuses on convenience and speed. 

Founded in December 2020 by Dhruv Gupta and TarunBhambra, Orange Health has established itself as an on-demand diagnostic leader, providing at-home sample collection services in cities such as Bengaluru, Gurugram, Delhi, Noida, and Ghaziabad. With a customer base exceeding 1 million and partnerships with over 1,000 clinics, the firm claims a 3x growth over the last two years and projects 100% growth this year.

“Today’s consumers want things available to them at their convenience, and quick commerce is the biggest example of this in the last four or five years. While you could wait 20 minutes for your chips, speed matters more when you’re sick,” cofounder Dhruv Gupta said.

“This process typically takes 18 hours in a traditional lab. Over time, we have streamlined the whole process to bring it down to six hours,” he added.

In June 2022, Orange Health secured $25 million in its Series B round, spearheaded by General Catalyst and Bertelsmann India Investments. Three months later, the company launched its first employee stock option plan and equity buyback program worth $1 million, highlighting its commitment to employee growth.

Currently operating in four metro cities, the company aims to strengthen its presence before expanding to other tier-1 cities.

Gupta said these four metro cities account for 25% of the diagnostic market. “Our primary focus right now, rather than pursuing wide geographic expansion, is to serve customers in these cities and build greater dominance. Probably over the next year or so, we will expand to the next set of metros and tier 1 cities, and then beyond that,” he added.

Additionally, Orange Health recently surpassed an annual revenue run rate of ₹100 crore and achieved profitability in Bengaluru. Orange Health operates six labs and is now poised to accelerate its innovation journey. Amazon’s $250 million Smbhav Venture Fund, which has previously backed startups like The Good Glamm Group and Smallcase, strengthens its confidence in the transformative potential of Indian startups. 

Commenting on the investment, Abhijeet Muzumdar, vice president corporate development and head of Amazon Smbhav Venture Fund, said, “Dhruv, Tarun and their team at Orange Health Labs have created a robust diagnostics service and we are excited to back them for the next phase of their growth.”  

The company is building a cutting-edge point-of-care blood analyzer that delivers complete blood count (CBC) results in under 10 minutes. The device requires just a finger-prick sample and is ideal for primary and emergency healthcare settings. Its low-maintenance design and high efficiency make it a revolutionary tool for the healthcare industry.

Providing immediate CBC results directly to physicians enables quicker and more informed decisions on patient care. This eliminates delays caused by transporting and processing clinical samples. Physicians benefit from the confidence to diagnose and treat conditions promptly. Patients experience improved outcomes, while the healthcare system saves costs by avoiding unnecessary treatments like inappropriate antibiotics. Additionally, life-saving interventions for conditions like sepsis, anemia, and thrombocytopenia can begin without delay, especially for critical cases like dengue patients.

Neuranics’ innovative design integrates compact, dry hematology technology with unmatched efficiency, allowing it to meet the growing demand for accurate and fast diagnostics.

Founded in 2021 by Praveen Kumar (CEO) and Ashutosh Patra (CTO), Neuranics addresses key gaps in diagnostic technology. Praveen, an IIT Delhi graduate, has extensive experience in healthcare tech and has worked on government initiatives like Corona Kavach and Aarogya Setu. Ashutosh, an alumnus of the SiB program at AIIMS, drives product innovation with expertise in optical sensing and mechanical engineering. Together, they’ve achieved milestones such as securing a patent, obtaining the CDSCO Test License, and receiving ethical approvals from AIIMS Delhi. The team is currently advancing through clinical trials.

Mitesh Shah, Co-founder of IPV, says, “Neuranics is tackling the problem of lengthy and complex blood testing processes with their point-of-care blood analyzer that makes complete blood count diagnosis faster and easier. This significantly improves patient care, especially in urgent cases. IPV believes in the startups innovative technology and envisions a future where the startups bring out more such necessary tools”.

Dr Megha Sharma, MD Pathologist and Chief Medical Evangelist at Neuranics, says, “Our point-of-care CBC analyzer represents a significant leap forward in diagnostic convenience and accessibility. By utilizing a simple finger-prick capillary blood sample. We have effectively eliminated the need for traditional venipuncture, making blood testing faster, less invasive, and more patient-friendly. This technology empowers healthcare providers to deliver immediate, actionable insights, even in resource-limited settings, ultimately improving patient outcomes especially in Primary health care centres for screening and at emergency setups for triage. ”

Neuranics has gained recognition through accolades like YourStory Tech30, Amazon-Sambhav, and the India-Sweden Innovation Challenge. These achievements highlight its potential to decentralize routine diagnostics, making tests for anemia, thalassemia, malaria, and leukemia faster and more accessible. 

Praveen Kumar, Co-founder & CEO of Neuranics, says, “We are re-imagining how we approach diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising quality. Our technology empowers clinicians with real-time data, transforming care delivery and elevating patient outcomes.

By leveraging AI on de-identified pathological imaging data generated by our analyzer, we aim to set a new gold standard for national screening programs. This innovative technology will elevate healthcare quality in India and establish the country as a global leader in point of care blood analyser.

We thank IPV for being with us in this journey. Working with IPV has been a streamlined and transformative experience. Their investment and guidance have empowered us to scale faster, innovate further, and bring our vision to life. IPV’s efficient processes and industry connections have been instrumental in our journey.”

In the $50 billion global CBC market, Neuranics is poised to lead the next wave of diagnostic technology. The company is setting new standards in healthcare diagnostics by focusing on precision robotics, machine vision, and microfluidics.

Understanding the critical role of communication in healthcare, SpeakX has conducted a comprehensive needs assessment to develop a tailored program specifically for Cloudnine Hospital’s nursing professionals. This customized program addresses the unique challenges faced by healthcare workers, focusing on essential areas such as patient and their families’ interactions, as well as teamwork and communication.

The program officially launched on October 10th, reaching 325 nurses at Cloudnine Hospital. The customized training includes interactive modules & exercises and real-life scenarios relevant to the healthcare context, ensuring that the learning experience is both engaging and applicable. 

Commenting on the recent collaboration, Arpit Mittal, Founder of SpeakX, said, “We are incredibly proud to support Cloudnine Hospital in its mission to provide exceptional healthcare services. Effective communication is the backbone of quality healthcare, and we believe that by empowering nurses with strong English communication skills, we can significantly enhance their ability to serve patients. This partnership represents an important step toward creating a more confident and capable nursing workforce, ultimately leading to better patient outcomes and satisfaction.”

In addition to this collaboration, SpeakX has recently garnered attention for its selection in the prestigious Google Startups Accelerator. As a pioneering platform revolutionizing English learning through Generative AI technology, SpeakX is set to join a cohort of 20 innovative startups, receiving tailored guidance and support to enhance product development and growth strategies. “Technology can truly change the face of education, especially for those who have been left behind. Right now, only 8% of people in India speak English well, which means many miss out on key opportunities for education, jobs, and personal and social growth. At SpeakX, we are tackling this challenge head-on,” added Arpit.

The Google for Startups Accelerator will provide SpeakX with access to Google’s AI technologies and resources, helping the platform further its mission of empowering users with personalized and engaging English learning experiences. With half of its user base from Tier 2 and Tier 3 cities, SpeakX is dedicated to making English education accessible to a diverse audience, including individuals from middle-income households.

In recent months, SpeakX has achieved significant growth by surpassing 10,000 paid subscribers monthly. Offering a personal AI companion at a fraction of the cost, SpeakX’s subscription model, priced at ₹299 per month, has helped the company generate an Annual Recurring Revenue (ARR) of $500,000. With $10 million in funding from Elevation and IndiaQuotient, SpeakX has carved a niche in the global language learning market.

About SpeakX

SpeakX is a cutting-edge platform revolutionizing how non-native speakers learn English through advanced Generative AI and Speech Technology. By tailoring lessons to each user’s specific learning needs, SpeakX provides personalized instruction and real-time feedback through AI companions that are available 24/7. Catering to every Indian, SpeakX helps users enhance their English skills and opens doors to new opportunities.

About Cloudnine Hospitals

Cloudnine Group of Hospitals is a chain of maternity and paediatric hospitals in India. The hospital offers a range of services, including prenatal and postnatal care, paediatric care and gynaecological treatments. It is equipped with advanced medical technology and staffed by experienced doctors and nurses.

The funds will accelerate QubeHealth’s tech development and enable new feature launches, such as embedded insurance, a gen-AI-powered recommendation engine, and a healthcare marketplace. The company aims to raise around $9 million in its forthcoming Series-A round.

“We are seeing massive growth, even though we are limited to the B2B-2C channel, for now,” said Chris George, co-founder & CEO of QubeHealth.

“Employees of our corporate clients are adding their family members and are paying for their healthcare multiple times in a month, giving us deep insights about out-of-pocket healthcare spending in India. We look forward to leveraging the support and guidance of these two institutional investors as we grow and prepare for our upcoming Series-A,” George said. 

QubeHealth-Pay, a mobile app, empowers Indians to pay for family healthcare bills from various fund sources, covering hospitals, clinics, doctors, and pharmacies. Users benefit from an instant cash-back discount on every payment and can access immediate medical financing if health insurance doesn’t cover the bill.

Employees and their families from major Indian companies, like Flipkart, Tata Teleservices, and 300 other employers, actively use the QubePay app to pay at any health or medical provider in India. QubeHealth has achieved over 400% growth this year by distributing its product through employers to employees and their families via a B2B2C channel. By the end of the financial year, Qube is on course to process over Rs 100 crore in healthcare payments.

Co-founder Brijraj Bhuptani mentioned that existing investors Together Fund, Fidelity’s Eight Roads Ventures, and F Prime Capital also participated in the funding round.

Spry Therapeutics, a company that develops software for physical healthcare centers, aims to capitalize on the growing trend of software products targeting the global market. Bhuptani, who previously served as the chief technology officer at Ola, stated that his goal is to target the largest market in the world first.

“U.S. healthcare is not just one big $4 trillion monolith. It is, in fact, thousand $4 billion opportunities,” Bhuptani said. “Anyone who wants to make a meaningful impact cannot do so by going wide and operating on the fringes. Spry is changing how PTs will manage their practice by enabling them to go deep.” 

Spry Therapeutics has a team of around 130 employees in India. The company supports processing insurance claims and provides integrated software for clinical management and administrative tasks at healthcare centers. Additionally, it offers financial services like payments and billing.

With the latest equity round, the company’s total funding has reached $25 million.

Within 18 months of its launch, Spry Therapeutics has partnered with 105 clinics in the US. With the new funds, the startup plans to establish a sales and service team in the US and focus on growing its client base, said Bhuptani.

The physical therapy market is expanding due to the increasing demand for rehabilitation after surgery and preventive care, which helps patients maintain long-term health.

“Spry is targeting the large market of small businesses which provide physical therapy but they lack the means to make insurance claims digitally. It will help solve a real need in the market,” said Kabir Kumar, partner at Flourish Ventures. 

Kumar highlighted India’s backend IT expertise, noting that a vast local talent pool is skilled in filing insurance claims for healthcare in the US. Spry is utilizing this talent to develop software tailored to that market.

Riyaz Rehman, the other co-founder, previously led the business at Ridlr until its acquisition by Ola in 2018.

The fund will join as a cofounder of the Gurgaon-based startup alongside Ankur Jain, the former chief product officer at BharatPe, and GV Sanjay Reddy, the chairperson of Reddy Ventures.

Jain and Reddy shared that the investment was completed last week, but the amount remains undisclosed. They did not reveal how much AI Fund invested or the percentage of stake acquired.

People aware of the development say that Ng’s fund has bought a 20-30% share in the company, which started in January of this year.

“AI is transforming healthcare, and Jivi takes an important step toward more equitable, precise, and personalized care,” said Andrew Ng, managing general partner at AI Fund. “Ankur and team are at the forefront of this transformation and are developing accessible and intelligent tools. AI Fund is excited to advance this vision together with Jivi.” 

Jivi’s CEO, Jain, says their AI products include a consumer health assistant to make healthcare more accessible and a doctor copilot to help healthcare workers. 

Reddy adds that they want to keep the core features free for everyone and will add paid features later. Top hospitals are testing the multilingual and multimodal platform, which will be available to the public soon. It uses AI to help patients diagnose, treat, and prevent, and it works for many different healthcare specialties.

The company says it gives patients quick, accurate answers to their health questions and makes personalized health reports with symptoms, possible diseases, and treatment choices.

“Our mission is to make healthcare more efficient, affordable, and accessible to everyone, regardless of location,” Jain said. 

Jain says Ng’s knowledge and ideas will help Jivi change global healthcare and make good care available to everyone. The platform uses a knowledge base with over 15 million documents, making it one of the biggest in this area. This includes medical journals and years of research.

Jivi helps doctors analyze patient data and make their work easier by reducing administrative tasks. This lets them spend more time preparing for consultations. Jivi is designed to help people everywhere, from rural areas to big city hospitals. It can also grow and change to make healthcare more fair, efficient, and available to everyone.